ClinicalTrials.gg
RecruitingNCT07860411Updated Oct 19, 2026

Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis With Nasal Polyps

An observational study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Nasal Polyps, sponsored by Harran University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Harran University · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 19, 2026Interventions changedNewly registered+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the sinonasal mucosa whose metabolic and immunologic mechanisms are incompletely understood. This prospective case-control study aims to characterize metabolic and immunologic biomarkers in patients with CRSwNP compared with control subjects. Nasal tissue and peripheral blood samples will be analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for free amino acid and carnitine/acylcarnitine profiles, and levels of interleukin-40 (IL-40), interleukin-6 (IL-6), and hypoxia-inducible factor-1 alpha (HIF-1α) will be measured by ELISA. The findings are expected to contribute to understanding disease pathogenesis and to identifying potential diagnostic biomarkers and therapeutic targets.

Read the detailed description

Adult patients presenting to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine with nasal obstruction and a histopathologically confirmed diagnosis of nasal polyposis (by punch biopsy or surgical specimen) will be enrolled. Nasal polyp tissue and peripheral blood samples will be collected from 40 patients with CRSwNP. The control group will consist of 40 patients undergoing septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps, from whom healthy nasal mucosa biopsies and peripheral blood samples will be obtained. Free amino acid and carnitine/acylcarnitine profiles will be determined in tissue and serum by LC-MS/MS, and IL-40, IL-6 and HIF-1α concentrations will be measured by ELISA. Metabolic and immunologic differences between nasal polyp tissue and healthy nasal mucosa, and their reflection in peripheral blood, will be compared between groups. Tissue and blood levels obtained from the same individual will be compared using paired tests, and correlations between metabolic parameters and immune markers will be assessed by Pearson or Spearman correlation analysis. In the CRSwNP group, associations of these biomarkers with disease severity, symptom scores and endoscopic findings will also be evaluated. The diagnostic performance of candidate biomarkers will be assessed by receiver operating characteristic (ROC) analysis. To our knowledge, IL-40 has not previously been investigated in CRSwNP.

02

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
  • Nasal Polyps

Browse trials for

Keywords

  • Metabolomics
  • LC-MS/MS
  • Interleukin-40
  • Interleukin-6
  • HIF-1 alpha
  • Biomarkers
  • Amino acids
  • Acylcarnitines
03

In context

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 47 observational studies indexed under Nasal Polyps.

Browse Nasal Polyps studies →

Lead sponsor

Harran University is the lead sponsor of 64 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients presenting with nasal obstruction to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine, Şanlıurfa, Turkey, with histopathologically confirmed chronic rhinosinusitis with nasal polyps (by punch biopsy or surgical specimen), and adult control patients without chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery at the same department.

Eligibility criteria

CRSwNP Group

Inclusion Criteria:

  • Age 18 years or older
  • Diagnosis of chronic rhinosinusitis with nasal polyps at the Otorhinolaryngology outpatient clinic
  • Diagnosis of nasal polyposis confirmed by histopathological examination of a punch or surgical specimen
  • No condition preventing the collection of tissue and peripheral blood samples within the scope of the study

Exclusion Criteria:

  • Acute upper respiratory tract infection or acute rhinosinusitis
  • History of systemic inflammatory or disease
  • History of or active malignant disease
  • Immunodeficiency or use of therapy
  • Use of systemic , biologic agents or immunomodulatory therapy within the last 4 weeks
  • Use of antibiotics for an acute infection within the last 4 weeks
  • Pregnancy or breastfeeding
  • Presence of an additional systemic disease severe enough to prevent participation in the study

Control Group

Inclusion Criteria:

  • Age 18 years or older
  • No history of nasal polyposis or chronic rhinosinusitis
  • Scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps
  • Collection of a healthy nasal mucosa biopsy during surgery poses no additional risk

Exclusion Criteria:

* Same exclusion criteria as the CRSwNP group

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • CRSwNP Group

    Adult patients diagnosed with chronic rhinosinusitis with nasal polyps according to EPOS 2020 criteria, with nasal polyposis confirmed histopathologically by punch biopsy or surgical specimen. Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.

    Other: Nasal polyp tissue and blood sampling

  • Control Group

    Adult patients without nasal polyposis or chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps. A healthy nasal mucosa biopsy is obtained during surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.

    Other: Nasal mucosa and blood sampling

Interventions

  • OtherNasal polyp tissue and blood sampling

    Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.

  • OtherNasal mucosa and blood sampling

    A healthy nasal mucosa biopsy is obtained during septoplasty, rhinoplasty or similar nasal surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.

06

What researchers measure

Primary outcomes

  1. Tissue and serum free amino acid and carnitine/acylcarnitine profiles

    Concentrations of free amino acids, free carnitine and acylcarnitines measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in nasal tissue and serum, compared between the CRSwNP and control groups.

    Time frame: At the time of tissue sampling (Day 0)

  2. Interleukin-40 (IL-40) levels in tissue and serum

    IL-40 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.

    Time frame: At the time of tissue sampling (Day 0)

Secondary outcomes

  1. Interleukin-6 (IL-6) levels in tissue and serum

    IL-6 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.

    Time frame: At the time of tissue sampling (Day 0)

  2. Hypoxia-inducible factor-1 alpha (HIF-1α) levels in tissue and serum

    HIF-1α concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.

    Time frame: At the time of tissue sampling (Day 0)

  3. Diagnostic performance of candidate biomarkers

    Area under the receiver operating characteristic curve (AUC), sensitivity and specificity of tissue and serum amino acid, carnitine/acylcarnitine, IL-40, IL-6 and HIF-1α levels for discriminating CRSwNP from control subjects.

    Time frame: At the time of tissue sampling (Day 0)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartActual
Mar 15, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Mar 10, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology · Sanliurfa, Turkey (Türkiye)
Show 1 removed
  • Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology · Sanliurfa, Turkey (Türkiye)
Oct 19, 2026
Interventions
Added Nasal polyp tissue and blood sampling·Nasal mucosa and blood sampling; removed Biospecimen collection
Oct 19, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology · Sanliurfa, Turkey (Türkiye)
    Show 1 removed
    • Harran University Faculty of Medicine Hospital, Department of Otorhinolaryngology · Sanliurfa, Turkey (Türkiye)
    Interventions Added Nasal polyp tissue and blood sampling·Nasal mucosa and blood sampling; removed Biospecimen collection
    + 1 other change: index terms
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860411
Lead sponsor
Harran University
Responsible party
Servet Erdemes (Assistant Professor of Otorhinolaryngology, Harran University) — Principal investigator
First posted
Oct 6, 2026
Start date
Mar 15, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Mar 10, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Mahmut Ağırtmış, MD
Contact
mahmutagirtmis@harran.edu.tr
+905012392163
Servet Erdemes, MD
principal investigator · Harran University
Mahmut Ağırtmış, MD
study director · Harran University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion